Portolan Capital Management’s Viking Therapeutics VKTX Stock Holding History

Portolan Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-138,748	Closed	-$3.35M	–	145
2025 Q1	$3.35M	Buy	138,748 +10,328	+8%	+$326K	0.25%	87
2024 Q4	$5.17M	Buy	128,420 +2,658	+2%	+$152K	0.35%	90
2024 Q3	$7.96M	Buy	125,762 +46,340	+58%	+$2.72M	0.58%	62
2024 Q2	$4.21M	Sell	79,422 -18,161	-19%	-$1.19M	0.35%	94
2024 Q1	$8M	Sell	97,583 -242,217	-71%	-$10.8M	0.61%	63
2023 Q4	$6.32M	Buy	+339,800	New	+$4.44M	0.55%	63

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Portolan Capital Management's VKTX Position: Q2 2025 in Review

Portolan Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 138,748 shares — an estimated $3.35M sold.

Portolan Capital Management first reported a position in VKTX in Q4 2023 and held it in 6 quarters. The position peaked at $8M in Q1 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Portolan Capital Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Portolan Capital Management sold 138,748 Viking Therapeutics shares in Q2 2025, an estimated $3.35M.
Portolan Capital Management first reported a position in Viking Therapeutics in Q4 2023 and held it in 6 quarters.
Portolan Capital Management's Viking Therapeutics position peaked at $8M in Q1 2024.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Portolan Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.